CD47 and myelodysplastic syndrome: Anti-CD47 monoclonal antibodies have been shown both in vivo and in vitro to reverse the anti- phagocytic signal and eliminate AML LSCs, suggesting their potential role in the treatment of AML and HR-MDS [60].